Arginine Adjunctive Therapy in Active Tuberculosis
Table 2
Clinical and laboratory findings in arginine and placebo groups at the end of the first and second months*.
Sign and symptom
Group
value
Arginine (%)
Placebo (%)
Constitutional symptoms
First month
11 (34.4)
19 (61.3)
0.032
Second month
3 (9.4)
8 (25.8)
0.085
Cough
First month
15 (46.9)
19 (61.3)
0.25
Second month
3 (9.4)
5 (16.1)
0.424
BMI < 18.5
First month
4 (12.5)
11 (35.5)
0.032
Second month
1 (3.1)
6 (19.4)
0.04
Positive sputum smear
First month
14 (43.8)
18 (58.1)
0.254
Second month
1 (3.1)
4 (12.9)
0.15
Anemia
First month
6 (18.8)
12 (38.7)
0.08
Second month
2 (6.3)
7 (22.6)
0.064
↑ ESR mm/h
First month
25 (78.1)
26 (83.9)
0.561
Second month
11 (34.4)
15 (48.4)
0.258
↑ CRP
First month
8 (25)
16 (51.6)
0.03
Second month
2 (6.3)
6 (19.4)
0.118
Final treatment success (end of sixth month)
32 (100%)
31 (100%)
—
Categorical variables were compared using the chi-square test or Fisher’s exact test where appropriate. Continuous variables were compared using the -test or the nonparametric Mann-Whitney test according to data distribution.
